Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex To Launch Menostar As Lowest Dose Estrogen Patch Approved For Osteoporosis Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

Low estrogen dose reduces need for concomitant progestin therapy in women who have a uterus. Berlex will study longer-term use following June 8 FDA approval.

You may also be interested in...



Berlex' Angeliq Approved, Will Launch In Mid-2006

The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.

Berlex' Angeliq Approved, Will Launch In Mid-2006

The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.

Massachusetts Medicaid Adds Prior Authorization For Elidel, Protopic

State’s decision to require prior authorization for Novartis’ Elidel and Astellas’ Protopic comes several months after FDA requested that labeling for the topical eczema agents include a “black box” warning for potential cancer risk. MassHealth removes prior authorization requirement for Berlex’ estrogen patch Menostar.

Topics

UsernamePublicRestriction

Register

PS059913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel